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Neurobiology of Disease

Neuronal-Targeted TFEB Accelerates Lysosomal
Degradation of APP, Reducing A␤ Generation and Amyloid
Plaque Pathogenesis
Qingli Xiao,1 Ping Yan,1 Xiucui Ma,2,4 Haiyan Liu,2,4 Ronaldo Perez,1 Alec Zhu,1 Ernesto Gonzales,1
X Danielle L. Tripoli,1 X Leah Czerniewski,1 Andrea Ballabio,5 John R. Cirrito,1 X Abhinav Diwan,2,3,4* and
X Jin-Moo Lee1*
1

Department of Neurology and the Hope Center for Neurological Disorders, 2Center for Cardiovascular Research in Department of Medicine, and
Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri 63110, 4John Cochran VA Medical Center, St.
Louis, Missouri 63108, and 5Telethon Institute of Genetics and Medicine, Pozzuoli, Naples, Italy 80078

3

In AD, an imbalance between A␤ production and removal drives elevated brain A␤ levels and eventual amyloid plaque deposition. APP
undergoes nonamyloidogenic processing via ␣-cleavage at the plasma membrane, amyloidogenic ␤- and ␥-cleavage within endosomes to
generate A␤, or lysosomal degradation in neurons. Considering multiple reports implicating impaired lysosome function as a driver of
increased amyloidogenic processing of APP, we explored the efficacy of targeting transcription factor EB (TFEB), a master regulator of
lysosomal pathways, to reduce A␤ levels. CMV promoter-driven TFEB, transduced via stereotactic hippocampal injections of adenoassociated virus particles in APP/PS1 mice, localized primarily to neuronal nuclei and upregulated lysosome biogenesis. This resulted in
reduction of APP protein, the ␣ and ␤ C-terminal APP fragments (CTFs), and in the steady-state A␤ levels in the brain interstitial fluid.
In aged mice, total A␤ levels and amyloid plaque load were selectively reduced in the TFEB-transduced hippocampi. TFEB transfection in
N2a cells stably expressing APP695, stimulated lysosome biogenesis, reduced steady-state levels of APP and ␣- and ␤-CTFs, and attenuated A␤ generation by accelerating flux through the endosome-lysosome pathway. Cycloheximide chase assays revealed a shortening of
APP half-life with exogenous TFEB expression, which was prevented by concomitant inhibition of lysosomal acidification. These data
indicate that TFEB enhances flux through lysosomal degradative pathways to induce APP degradation and reduce A␤ generation.
Activation of TFEB in neurons is an effective strategy to attenuate A␤ generation and attenuate amyloid plaque deposition in AD.
Key words: Alzheimer’s disease; amyloid; amyloid precursor protein; lysosome; TFEB

Significance Statement
A key driver for AD pathogenesis is the net balance between production and clearance of A␤, the major component of amyloid
plaques. Here we demonstrate that lysosomal degradation of holo-APP influences A␤ production by limiting the availability of
APP for amyloidogenic processing. Using viral gene transfer of transcription factor EB (TFEB), a master regulator of lysosome
biogenesis in neurons of APP/PS1 mice, steady-state levels of APP were reduced, resulting in decreased interstitial fluid A␤ levels
and attenuated amyloid deposits. These effects were caused by accelerated lysosomal degradation of endocytosed APP, reflected
by reduced APP half-life and steady-state levels in TFEB-expressing cells, with resultant decrease in A␤ production and release.
Additional studies are needed to explore the therapeutic potential of this approach.

Introduction
In AD, increased generation of the A␤ peptide in neurons synergizes with impaired A␤ removal from the interstitial fluid (ISF) in
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driving extracellular amyloid plaque formation (Haass et al.,
2012) and the resultant neuropathogenesis (Bloom, 2014). After
synthesis in the endoplasmic reticulum, APP is trafficked from
the Golgi to the plasma membrane, where it is cleaved by
␣-secretases within the A␤ peptide fragment region, in a manner
that precludes A␤ generation (i.e., nonamyloidogenic or ␣-cleavage; Rajendran and Annaert, 2012). Alternately, APP is endocytosed, and sequentially cleaved by a ␤-secretase (BACE1) and
then the ␥-secretase complex (comprised of presenilins, nicastrin, APH-1, and PEN2) within endosomes, to generate A␤ peptides (amyloidogenic cleavage; Rajendran and Annaert, 2012).
Accumulating evidence suggests that dysregulation of endocytosis (Harold et al., 2009; Ginsberg et al., 2010) with accumulation
of large endosomes within neurons, as observed in preclinical
stages of AD pathology (Cataldo et al., 2000) and in neurons
transdifferentiated from fibroblasts of patients with AD (Israel et
al., 2012), increases the proclivity for amyloidogenic processing
of APP.
Endocytosed APP can be sorted back to the Golgi (Morel et
al., 2013) or trafficked to lysosomes along with other endosomal cargo (Théry et al., 2002). Indeed, a large fraction of
full-length APP is degraded within lysosomes (Caporaso et al.,
1992, 1994; Golde et al., 1992; Haass et al., 1992). Experimental inhibition of lysosome function markedly prolongs APP
half-life (Caporaso et al., 1992) and impairs endocytotic flux
with accumulation of enlarged vesicles in dystrophic neurites
mimicking AD pathology (Lee et al., 2011), with increased
BACE1 (Chia et al., 2013) and ␤-C-terminal fragment (Golde
et al., 1992; Sannerud et al., 2011) resulting in markedly increased A␤ generation. Relevant to this discussion is that impaired lysosomal function is observed with aging (Kato et al.,
1998; Cuervo and Dice, 2000; Wolfe et al., 2013) and with loss
of presenilins (due to mutations causing familial AD; Lee et al.,
2010; Neely et al., 2011; Coen et al., 2012), and is suspected
with polymorphisms in genes coding for lysosomal proteins,
which confer increased risk for sporadic AD, including phospholipase D3 (Cruchaga et al., 2014), cystatin C (Hua et al.,
2012), and Cathepsin D (Schuur et al., 2011). Also, levels of
APP, its ␤-CTF, and A␤ are increased in mouse models of
lysosome storage disorders, namely, Neimann-Pick disease
(Kodam et al., 2010), mucolipidoses (Keilani et al., 2012), and
sphingolipidoses (Tamboli et al., 2011). These observations
incriminate lysosomal dysfunction as the common cellular
mechanism in provoking increased A␤ generation and impaired A␤ removal (Funk and Kuret, 2012; Peric and Annaert,
2015).
As a therapeutic strategy to address lysosomal insufficiency in
astrocytes, we previously evaluated activation of transcription
factor EB (TFEB), a master inducer of lysosomal degradative
pathways (Settembre et al., 2013a), and demonstrated that astrocytic TFEB expression stimulates A␤ uptake and its lysosomal
degradation to reduce ISF A␤ (Xiao et al., 2014). In this study, we
evaluated the efficacy of neuronal TFEB activation in enhancing
lysosomal degradation of APP to reduce A␤ levels and attenuate
amyloid plaque pathogenesis.

Materials and Methods
Studies in animal models. APP/PS1 transgenic mice (B6C3-Tg (APPswe/
PS1⌬E9)85Dbo/Mmjax) of either sex were obtained from The Jackson
Laboratory (Jankowsky et al., 2004) and injected with AAV8 viral particles (generated by the Hope Center Viral Core at Washington University)
driving expression of TFEB (AAV8-CMV-FLAG-TFEB) or GFP as control (AAV8-CMV-GFP), each with 2 l of 1.5 ⫻ 10 12 viral genomes per
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milliliter into bilateral hippocampi at 6 months of age, as described previously (Xiao et al., 2012). Wild-type mice of either sex were also injected
with AAV8-CMV-FLAG-TFEB or AAV8-CMV-GFP at 4 months of age
to assess the effect of TFEB transduction on endogenous APP processing
after 4 months. Before injection, AAV particles were subjected to two
rounds of cesium chloride gradient purification and titers were quantified by assessment of viral genomes. For plaque load studies, TFEB or
control-transduced APP/PS1 mice (six males and eight females per
group) were killed 4 months later. One hemisphere was fixed and
coronal sections (50 m) were cut for histological analysis (X-34
staining and HJ3.4 immunostaining). The other hemisphere was snap
frozen on dry ice and stored at ⫺80°C for biochemical analysis
(ELISA and immunoblotting). To assess the abundance of A␤ species
in predepositing mice, the abovementioned AAV viral vectors were
injected into the hippocampi of APP/PS1 mice of either sex at 2
months of age and the animals were killed 1 month later. All animal
care and surgical procedures were approved by the Animal Studies
Committee of Washington University School of Medicine in accordance with guidelines of the NIH.
In vivo microdialysis. AAV particles driving expression of TFEB
(AAV8-CMV-FLAG-TFEB) or GFP as control (AAV8-CMV-GFP)
were transduced by stereotactically guided injection in the hippocampus of 2-month-old APP/PS1 transgenic mice of either sex followed
by in vivo microdialysis, 1 month later, as previously described (Cirrito et al., 2003, 2011). All studies were initiated at the same time of
day. Briefly, a guide cannula (BR-style; Bioanalytical Systems) was
implanted and cemented with the tip at coordinates: bregma ⫺3.1
mm, midline ⫺2.5 mm, 1.2 mm below dura at a 12° angle. A 2 mm
microdialysis probe was then inserted into the hippocampus that
contained a 38 kDa MWCO semipermeable membrane (Bioanalytical
Systems) allowing molecules smaller than this cutoff to diffuse into
the probe. A␤ capable of entering the probe is dubbed “exchangeable
A␤” (eA␤; Cirrito et al., 2003). The probe was flushed with 0.15%
bovine serum albumin (Sigma) in an artificial CSF perfusion buffer at
a constant rate (1.0 l/min). The effluate was collected into a refrigerated fraction collector and assayed by sandwich ELISA for A␤x-40
peptides at the end of each experiment. During microdialysis, animals
were housed in specially designed cages to permit free movement and
ad libitum food and water while ISF A␤ was sampled. Baseline levels of
ISF A␤ were sampled every 90 min between hours 9 and 16 (after the
microdialysis probe is inserted) and averaged to determine the “baseline ISF A␤ level” in each mouse. Absolute in vivo concentration of
ISF eA␤ for each mouse was determined by correcting for the 20.8%
recovery (1.0 l/min) as obtained by the interpolated zero flow
method described previously (Menacherry et al., 1992; Cirrito et al.,
2003). At hour 16 (t ⫽ 0), a ␥-secretase inhibitor, Compound E (200
nM reverse microdialysis; synthesized by AsisChem), was administered directly to the hippocampus by adding the drug to the microdialysis perfusion buffer. ISF A␤ was then sampled every 60 min for an
additional 8 h. This enabled measurement of the elimination half-life
of endogenous ISF A␤ in vivo as described previously (Cirrito et al.,
2003).
Immunohistochemistry. Frozen brain sections were incubated in 0.3%
H2O2 in TBS for 10 min and blocked with 3% dry milk in TBS-X (0.25%
Triton X-100 in TBS) for 1 h, followed by incubation with HJ3.4 antibody
(anti-A␤-1-13; Roh et al., 2012) overnight. Thereafter solution A from
Vectastain ABC kit (1:400) was applied for 1 h, followed by 0.025% DAB
in 0.25% NiCl2 and 0.05% H2O2 for 10 –15 min. The slices were placed
on glass slides, dried overnight, dehydrated and mounted, and imaged
with confocal microscopy (Zeiss LSM).
X-34 plaque staining. Brain slices were mounted on SuperFrost Plus
slides, permeabilized with 0.25% Triton X-100 for 30 min, and stained
with X-34 (dissolved in 40% ethanol, 60% water, pH 10.0; a generous gift
from Robert Mach, Washington University, St. Louis, MO) for 20 min.
Thereafter the tissue was thoroughly rinsed in PBS and mounted with
Fluoromount mounting media.
Amyloid plaque quantification. Fifty micrometer thick brain sections
were collected every 300 ms from the rostral anterior commissure to
caudal hippocampus. For plaque imaging, sections were stained with
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X-34 or immunostained with HJ3.4 anti-A␤ antibodies. High-resolution
digital images of the stained brain slices were obtained with the NanoZoomer Digital Scanner (Hamamatsu Photonics). The total area of plaque
coverage was measured using NIH ImageJ in the region of the hippocampus or piriform cortex (devoid of viral transduction) and expressed as
percentage total area for each slice. Results from n ⫽ 4 sections were
averaged to represent each animal.
Immunofluorescence. Paraffin-embedded brain sections were washed
with PBS and permeabilized with 0.3% Triton X-100 in PBS for 20 min
followed by blocking. For double labeling, a mixture of the following
antibodies was used: mouse anti-TFEB (MyBioSource, 1:100), rabbit
anti-NeuN (Abcam; 1:100), rabbit anti-GFAP (Sigma; 1:100), and rabbit anti-Iba1 (Wako Chemicals; 1:1000). A secondary antibody mixture
of Alexa Fluor 488-conjugated goat anti-mouse IgG and Alexa Fluor
594-conjugated goat anti-rabbit IgG (Invitrogen) was applied. Sections
were imaged by confocal microscopy (Zeiss LSM).
Neuronal counts. Stereological analysis for neuronal counts was performed on sections stained with 0.05% cresyl violet solution, as previously described (Xiao et al., 2014). Briefly, cresyl violet-stained cells with
nuclei imaged within the inclusive zone of each dissector frame were
counted in four equally spaced sections (50 m apart) in the dorsal
hippocampus of strata pyramidale CA1 and CA3, using a computerbased stereology system (Stereo Investigator; MicroBrightField) with the
optical fractionator (West et al., 1991).
In vitro studies. N2a cells stably expressing the human APP695
construct (N2a-APP695) were grown in DMEM/Opti-MEM (50:50)
supplemented with 5% FBS and 200 g/ml G418 and transfected with
FLAG-tagged murine TFEB or empty vector, as described previously
(Xiao et al., 2014). We observed ⬎90% efficiency for transfection of
exogenous TFEB (or GFP as control) in these in vitro studies. For assessment of APP half-life by cycloheximide chase assay, N2a-APP695 cells
transfected with TFEB (or control) were treated with 50 g/ml cycloheximide followed by preparation of cellular extracts at various time intervals for immunoblotting for APP. To inhibit lysosome acidification and
function, studies were performed in the presence of bafilomycin A1 (100
nM), as previously described (Xiao et al., 2014). Studies with cell-surface
biotinylation to assess internalization of APP were performed as described previously (Xiao et al., 2012). Briefly, cells cultured in 6-well
plates were washed with cold PBS and surface proteins were labeled with
the nonmembrane-permeant, cleavable biotin derivative, sulfo-NHSSS-biotin (1 mg/ml in PBS). Cells were kept at 4°C for 30 min in the dark
and gently rocked during the incubation period. The biotin reagent was
quenched by treating the cells with two 15 min washes of 0.1 M glycine in
PBS. Cells were rinsed with PBS and lysed in RIPA buffer containing 50
mM Tris-HCl, pH 7.5; 150 mM NaCl; 1% (v/v) Nonidet P-40; 0.5% (w/v)
deoxycholate; and 1⫻ protease inhibitor mixture. Lysates were incubated with Dynabeads MyOne Streptavidin T1 (Invitrogen) for 2 h in a
rotary mixer to isolate biotin-labeled proteins. A cohort of surface biotinlabeled cells was incubated for 0, 1, 2, 3, 5, 7.5, 10, 20, and 30 min at 37°C to
allow internalization, followed by rapid cooling on ice to stop endocytosis.
To cleave biotin exposed at the cell surface, these cells were incubated three
times for 20 min at 4°C with 50 mM 2-mercaptoethanesulfonic acid (Sigma)
in 50 mM Tris-HCl, pH 8.7; 100 mM NaCl; and 2.5 mM CaCl2. After thorough
rinsing with PBS containing 20 mM HEPES, cells were lysed in RIPA buffer,
and internalized biotinylated proteins were immunoprecipitated with
streptavidin followed by immunoblotting for APP (CT695; Invitrogen). Uptake of biotin-labeled transferrin (T3915; Sigma) was assessed in parallel in
TFEB and vector-transfected cells to determine the effect of TFEB on
clathrin-mediated endocytosis. Immunofluorescence was performed on
C17.2 cells cotransfected with Cer-APP-YFP and TFEB or control vector and
incubated with LysoTracker Red (L7526; Invitrogen) to label the lysosome
compartment, and live cells were examined by confocal microscope (Zeiss
LSM).
A␤ ELISA. A␤ species in cell lysates and media from transfected N2aAPP695 were detected by sandwich ELISA, as previously described (Xiao
et al., 2014). To detect total A␤ in the hippocampus in 3-month-old
mice, dissected tissue was sequentially homogenized in PBS followed by
RIPA buffer to obtain detergent-soluble A␤ at an age when plaques are
not observed (Yan et al., 2009), and samples were pooled for analysis. In
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aged mice (10 months old, when plaques are abundant), hippocampal
tissues were sequentially homogenized in PBS followed by 5 M guanidine
in TBS, pH 8.0 (to extract fibrillar and membrane-bound A␤). For
ELISA assays, A␤x-40 and A␤x-42 peptides were captured with mouse
monoclonal-coating antibodies HJ2 (anti-A␤35-40) and HJ7.4 (antiA␤37-42) or HJ5.1 (anti-A␤13-28), respectively, as previously described
(Kim et al., 2009; Xiao et al., 2014). HJ5.1 (anti-A␤13-28), a biotinylated
antibody targeting the central domain, or HJ3.5 (anti-A␤1-13, provided
by Dr. David Holtzman, Washington University School of Medicine, St.
Louis, MO), which targets the N-terminal amino acids, was used as the
detecting antibody, followed by streptavidin-poly-HRP-40 (Fitzgerald
Industries). All ELISA assays were developed using Super Slow ELISA
TMB (Sigma) and absorbance read on a Bio-Tek Epoch plate reader at
650 nm. Standard curves were generated from synthetic human A␤1– 40
or A␤1– 42 peptides (American Peptide).
Quantitative PCR. Real-time PCR was performed as described previously (Ma et al., 2012). Briefly, total RNA was prepared from transfected
N2a-APP695 cells or AAV-transduced hippocampus using an RNA-easy
mini kit (Qiagen), and cDNA was synthesized with 1 g of total RNA
using the SuperScript III first-strand synthesis system (Invitrogen). One
microliter of cDNA template was mixed with 12.5 l of 2 ⫻ SYBR Green
PCR Master Mix (Invitrogen) and subjected to quantitative PCR in triplicate under the following conditions: 50°C, 2 min; 95°C, 10 min; followed by 40 cycles of 95°C, 15 s; 60°C, 1 min in the ABI7500 Fast
RealTime PCR system. The housekeeping gene GAPDH was also amplified in parallel as a reference for the quantification of transcripts. Primer
sequences used have been previously described (Xiao et al., 2014).
Immunoblotting. Protein samples were run on 4 –12% Bis-Tris gels.
Blots were probed with the following antibodies: FLAG (Sigma; 1:1000),
TFEB (MyBioSource; 1:500), LAMP1 (Santa Cruz Biotechnology;
1:500), Cathepsin B (Abcam; 1:500), Cathepsin D (a generous gift from
Stuart Kornfeld, Washington University, St. Louis, MO; 1:2000), APP
CT695 (to detect both full-length APP and C-terminal fragments; Invitrogen; 1:500), 6E10 (to detect sAPP␣; Covance; 1:1000), Adam10 (Santa
Cruz Biotechnology; 1:100), Adam17 (Millipore; 1:1000), BACE1 (Cell
Signaling Technology; 1:1000), Psen1 (Santa Cruz Biotechnology;
1:200), nicastrin (Thermo Scientific; 1:1000), IDE (Abcam; 1:2000), neprilysin (Millipore; 1:500), MMP2 (Abcam; 1:1000), MMP9 (Abcam;
1:1000), HRP-conjugated biotin (Cell Signaling Technology; 1:1000),
and actin (Sigma; 1:2000). Normalized band intensity was quantified
using ImageJ software.
Statistical analysis. All data are shown as Mean ⫾ SEM. Data were
analyzed by two-tailed Student’s t test for detecting significant differences between two groups. Differences among multiple groups were analyzed by one-way and two-way ANOVA for one and two independent
variables, respectively, followed by post hoc Tukey’s test. Statistical significance was pegged at p ⬍ 0.05 (*p ⬍ 0.05 and **p ⬍ 0.01).

Results
AAV-CMV-TFEB transduces TFEB specifically in neurons of
APP/PS1 mice with upregulated lysosome abundance
Lysosomal dysfunction is speculated to play a central role in enhanced A␤ generation in neurons (Lee et al., 2010; Neely et al.,
2011; Coen et al., 2012; Funk and Kuret, 2012; McBrayer and
Nixon, 2013; Wolfe et al., 2013) or its impaired clearance (WyssCoray et al., 2003; Majumdar et al., 2011; Lee et al., 2012; Kanekiyo et al., 2013). In previous studies, we demonstrated that
targeting expression of TFEB, a master inducer of lysosomal biogenesis (Sardiello et al., 2009; Settembre et al., 2011, 2013b), specifically to astrocytes, stimulated lysosome biogenesis and
function resulting in accelerated A␤ uptake and degradation
(Xiao et al., 2014). In the current study, we explored the hypothesis that enhancing lysosomal biogenesis in neurons with exogenous expression of TFEB will stimulate lysosomal degradation of
holo-APP to attenuate A␤ production. Accordingly, we performed stereotactically guided injections of AAV8 particles encoding a CMV promoter-driven construct to transduce TFEB
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(AAV8-CMV-FLAG-TFEB; and AAV8CMV-GFP as control) in the hippocampus of 6-month-old APP/PS1 mice, at a
stage of early plaque deposition and
growth (Yan et al., 2009). Stereotactic
AAV injections consistently resulted in
widespread transduction in the hippocampus (data not shown). As we observed previously (Xiao et al., 2012), the CMV
promoter-driven construct specifically resulted in TFEB expression in neurons with a
neuron-specific marker, NeuN, and not
in astrocytes or microglia (Fig. 1A). Importantly, exogenous TFEB localized to
the neuronal nuclei (Fig. 1A) and hippocampal extracts from AAV8-TFEBtransduced mice demonstrate robust
overexpression with TFEB (11-fold increase over control, p ⬍ 0.01; N ⫽ 3 per
group) with increased abundance of lysosomal proteins, LAMP1, and Cathepsin B and Cathepsin D (Fig. 1 B, C), two
lysosomal proteases that have been implicated in APP degradation (Higaki et
al., 1996; Mueller-Steiner et al., 2006).
Neuronal TFEB expression drives
reduced APP abundance, in vivo
APP695 is synthesized and processed primarily in neurons, where its sequential
cleavage via the ␤- and ␥-secretases results
in generation of amyloidogenic A␤ peptides (Hartmann et al., 1997; Kamenetz et
al., 2003). Alternately, APP processing can
proceed via ␣-secretases in a manner that Figure 1. AAV8-CMV-TFEB drives lysosome biogenesis in neurons. A, Representative confocal images demonstrating expresprecludes A␤ generation (Haass et al., sion of TFEB (green) in various CNS cell types marked by the expression of NeuN (neurons; red, top), GFAP (astrocytes; red, middle),
2012). Studies have demonstrated that a and Iba-1 (microglia; red, bottom) in the hippocampus of APP/PS1 mice injected with AAV8-CMV-FLAG-TFEB particles. The boxed
large fraction of full-length APP protein is inserts (upper left corners) demonstrate magnified images of TFEB-expressing cells. B, C, Immunoblots (B) with quantification (C)
of lysosomal proteins in extracts from hippocampi transduced with AAV8-CMV-FLAG-TFEB (TFEB) or AAV8-CMV-GFP (GFP). N ⫽ 3
also degraded within lysosomes, which per group; **p ⬍ 0.01.
may limit the pool of APP available for ␣-,
␤-, and ␥-cleavage (Caporaso et al., 1992,
these data suggest that TFEB expression facilitates holo-APP degra1994; Golde et al., 1992). Given that TFEB drives upregulation of
dation via pathways that do not involve APP processing by
the lysosomal machinery, we examined the effect of neuronal
␣-cleavage or sequential ␤- and ␥-cleavage.
TFEB expression on abundance of APP and its various cleavage
fragments. TFEB-transduced hippocampal extracts demonstrated a 28% reduction in APP protein abundance, accompanied
Neuronal TFEB expression reduces ISF A␤ levels, in vivo
A␤ peptides are released into the ISF and removed via cellular
by a matching 31 and 36% reduction in ␣-CTF and ␤-CTF (Fig.
2 A, B). Given previous observations that amyloid pathogenesis is
uptake and degradation, extracellular proteolysis, or transport
accelerated in female mice (Callahan et al., 2001), we examined
across the blood– brain barrier. Consequently, the steady-state
the effects of TFEB transduction in male and female mice sepalevel of A␤ in the ISF is determined by the balance between its rate
rately. We observed comparable reductions in APP in the two
of production and degradation. Considering that exogenous
sexes (by 29% in males vs 30% in females; data not shown). These
TFEB expression results in a reduction in total APP levels with a
data show that the effect of neuronal TFEB expression on APP
parallel reduction in abundance of its cleaved fragments (Fig.
2 A, B), we hypothesized that TFEB transduction will attenuate
abundance is independent of gender.
A␤ production resulting in reduced A␤ steady-state levels in the
The reduction in APP abundance was not caused by a difference
ISF. Accordingly, we transduced 2-month-old APP/PS1 mice
in the transcript levels for the transgenically expressed human
with AAV8-CMV-FLAG-TFEB and control AAV8-CMV-GFP
APP695 protein (Fig. 2C) or in the expression of ␣-secretases and
components of the ␤- and ␥-secretase machinery between the TFEB
viral particles and performed in vivo microdialysis 1 month later
and control-transduced hippocampi (Fig. 2C–E). Importantly,
to determine whether neuronal TFEB expression impacts ISF A␤
at a time point before deposition of plaques (Yan et al., 2009) to
TFEB-transduced hippocampi did not demonstrate a difference in
avoid a potential confounding influence from exchangeable
neuronal counts compared with control (Fig. 2F), ruling out neuronal toxicity as the underlying cause for these observations. Together
plaque-bound A␤ pool. TFEB-transduced mice demonstrated a
with the proportionately comparable reductions in various CTFs,
57% reduction in steady-state ISF A␤ levels compared with con-
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Figure 2. Neuronal TFEB transduction results in reduced APP abundance. A, B, Immunoblot (A) with quantitation (B) of APP and its ␣- and ␤-CTFs in APP/PS1 mouse hippocampi transduced with
AAV8-CMV-FLAG-TFEB (TFEB) or AAV8-CMV-GFP (GFP). N ⫽ 6 per group (n ⫽ 3 males and n ⫽ 3 females); **p ⬍ 0.01. Representative immunoblot is from male mouse tissues. C, Expression of
transcripts coding for various components of the APP-processing machinery in hippocampal tissues transduced with AAV8-CMV-FLAG-TFEB (TFEB) or AAV8-CMV-GFP (GFP). N ⫽ 5 per group. No
statistically significant differences were noted for any of the transcripts. D, E, Immunoblot (D) and quantitation (E) of APP-processing machinery proteins in hippocampi transduced with TFEB (or GFP
as control, as in A). N ⫽ 3 per group. F, Neuronal counts in the CA1 and CA3 layers of the hippocampi from AAV8-CMV-FLAG-TFEB (TFEB) and AAV8-CMV-GFP (GFP)-transduced APP/PS1 mice. N ⫽
4 per group.

trols (Fig. 3A). After steady-state measures of ISF A␤ were obtained, a potent ␥-secretase inhibitor, Compound E, was
administered to inhibit APP cleavage to A␤ (Cirrito et al., 2011),
and ISF was sampled for an additional period of 8 h to determine
the elimination rate (half-life) of pre-existing A␤ (Fig. 3A), which
was observed to follow first-order kinetics in both control and
TFEB-transduced mice (Fig. 3B). We observed a modest 24%
reduction in half-life of ISF A␤ in CMV-TFEB-transduced hippocampi, indicating that neuronal TFEB transduction also accelerates A␤ removal from ISF (Fig. 3B). That steady-state ISF A␤
levels are reduced by 57%, but half-life is reduced by only 24%,
strongly suggests that TFEB has only a minor role in enhancing
ISF A␤ clearance with the primary effect instead on reducing A␤
production. Indeed, previous studies have demonstrated that
neurons take up A␤ via endocytosis and macropinocytosis, and it
is conceivable that TFEB transduction stimulates A␤ uptake in
neurons via the latter similar to our studies with astrocytetargeted TFEB expression (Xiao et al., 2014). Importantly, the
effect of exogenous TFEB on reduction in ISF A␤ levels and A␤
half-life was comparable in both sexes (data not shown). We
also explored the possibility that TFEB transduction could
enhance extracellular degradation of A␤, but did not observe
any alteration in the transcript levels for known A␤metabolizing enzymes (MMP2, MMP9, IDE, or neprilysin) in
TFEB-transduced hippocampi (Fig. 3C). Analogously, the
protein abundance for these enzymes was unchanged (MMP2,
MMP9, and IDE) or modestly reduced (neprilysin; Fig. 3 D, E),
suggesting that regulation of extracellular proteases is unlikely
to contribute to a reduction in ISF A␤ levels with neuronal
TFEB transduction.

Importantly, total immunodetectable A␤ levels were also
reduced in the hippocampal extracts from TFEB-transduced
mice at this early stage of amyloid pathogenesis, compared
with controls (Fig. 3 F, G), confirming that the reduction in
steady-state levels of ISF A␤ was not due to intracellular A␤
accumulation. Together with the reduction in APP abundance
and that of its various cleaved fragments (Fig. 2 A, B), these
data point to a predominant effect of neuronal TFEB expression on attenuating A␤ generation with a modest effect on
accelerating A␤ removal as the primary driver of reduced
steady-state ISF A␤ levels.
Neuronal TFEB expression reduces A␤ levels and amyloid
plaques in APP/PS1 transgenic mice
ISF A␤ levels correlate with amyloid plaque pathology (Bero et
al., 2011), supporting the hypothesis that A␤ aggregates into amyloid plaques in a concentration-dependent manner, in vivo. Indeed, studies from our laboratory as well as others have
demonstrated that strategies to reduce ISF A␤ levels drive a reduction in amyloid plaque deposition (Cramer et al., 2012; Sheline et al., 2014; Xiao et al., 2014). Accordingly, we posited that
neuronal TFEB transduction will drive reduction in fibrillar A␤
aggregates and attenuate deposition of amyloid plaques in aging
APP/PS1 mice. To investigate this premise, we subjected TFEBtransduced (and control) hippocampal tissue to sequential homogenization in PBS followed by guanidine to quantify A␤ in
PBS-soluble and PBS-insoluble fractions. In addition, we performed A␤ immunohistochemistry and X-34 staining to assess
A␤ and amyloid load, respectively. As shown (Fig. 4A–C), TFEB
transduction resulted in a 40 and 50% reduction in soluble A␤40
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Figure 3. Neuronal TFEB transduction reduces ISF A␤ levels, in vivo. A, Assessment of A␤ levels by in vivo microdialysis in 3-month-old APP/PS1 mice transduced with AAV8-CMV-FLAG-TFEB
(TFEB) and AAV8-CMV-GFP (GFP) with serial hourly measurements. N ⫽ 8 mice in TFEB group, n ⫽ 9 mice in GFP group. At t ⫽ 0, mice were continually administered Compound E directly to the
hippocampus (200 nM, reverse microdialysis) followed by hourly sampling for A␤. Inset shows mean absolute in vivo “exchangeable” A␤ (eA␤x-40) concentration averaged over a 9 h period before
drug administration; *p ⬍ 0.05. B, Semilog plot of decline in percentage basal ISF A␤ levels during administration of Compound E in animals in A. Inset shows A␤ half-life in the two groups; *p ⬍
0.05. C–E, Transcript levels (C) and protein abundance [immunoblot (D) with quantitation (E)] for enzymes implicated in extracellular A␤ metabolism in hippocampal tissue from AAV8-CMV-FLAGTFEB (TFEB) and AAV8-CMV-GFP (GFP)-transduced APP/PS1 mice. N ⫽ 5 per group; **p ⬍ 0.01.F, G, A␤40 and A␤42 levels in dissected hippocampal tissues from AAV8-CMV-FLAG-TFEB (TFEB) and
AAV8-CMV-GFP (GFP)-transduced APP/PS1 mice at 3 months of age. Tissue was homogenized first in PBS (D) then in RIPA (E) quantified with ELISA assay. HJ2 and HJ7.4 antibodies were used for
capture A␤40 and A␤42, respectively, and HJ5.1 antibody was used for detection. N ⫽ 6 mice per group; **p ⬍ 0.01.

and A␤42, and 36 and 35% reduction in insoluble A␤40 and
A␤42, respectively, compared with controls, by an ELISA assay to
differentially capture the two species by specific C-terminal antibodies. To confirm these findings, we also used an alternate A␤
peptide capture and detection strategy using a combination of
antibodies targeting distinct epitopes at the central domain
(HJ5.1) and N terminus (HJ3.5), as previously described (Xiao et
al., 2014), and observed a 29 and 31% reduction in the soluble
and insoluble levels of all A␤ species in TFEB-transduced hippocampi (Fig. 4A–C). This suggests a uniform reduction in A␤
levels rather than a reduction in specific truncated fragments with
exogenous TFEB expression.
This was accompanied by a 35% reduction in X-34-stained
amyloid deposits (Fig. 4 D, E) and a 40% reduction in A␤-

immunostained amyloid plaque load (Fig. 4G,H ). Importantly,
as we have observed previously with astrocytic expression of exogenous TFEB (Xiao et al., 2014), the effect of neuronal TFEB
transduction on amyloid deposition was localized to the hippocampus (see area outlined with dotted line in Fig. 4D and G
and quantitation in E and H ), which was targeted for TFEB expression by stereotactic injection and not in the cortical areas that
are distant from the site of AAV transduction. It is interesting to
note that the degree of reduction in plaque load mirrored that of
the reduction in A␤ levels (Fig. 4 B, C) in the aged mice and that of
the reduction in ISF steady-state A␤ (Fig. 3 A, B) and hippocampal A␤ in the predepositing mice (Fig. 3 F, G), attesting to a consistent effect of TFEB on A␤ generation throughout the various
stages of amyloid pathogenesis. It is also noteworthy that TFEB-
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transduction had a comparable effect on amyloid plaque load
reduction in either sex (Fig. 4 F, I ), as we have previously observed (Xiao et al., 2014).These data suggest that TFEB
expression in neurons attenuates amyloid plaque deposition via
reducing A␤ generation.
Neuronal TFEB transduction reduces APP and A␤ levels in
wild-type mice
To exclude the possibility that TFEB primarily affects the processing of the mutant APP695 protein, which is co-overexpressed
with a familial AD risk conferring ⌬E9 mutant presenilin-1 protein in the APP/PS1 mice (Jankowsky et al., 2004), we examined
the effect of neuronally transduced TFEB on the abundance of
endogenous wild-type APP protein and its ␣- and ␤-CTFs in
hippocampi of wild-type mice versus those in GFP-transduced
hippocampi as controls. Remarkably, TFEB transduction led to a
comparable degree of reduction in abundance of total endogenous APP and levels of the ␣- and ␤-CTFs (Fig. 5 A, B) mimicking
its effect in APP/PS1 transgenic mice (Fig. 2 A, B). This translated
into a 27 and 21% reduction in A␤40 and A␤42 species (Fig. 5C),
respectively, indicating that TFEB also alters the metabolism of
wild-type APP protein to reduce A␤ generation.
TFEB expression attenuates A␤ generation, in vitro
To confirm that TFEB expression results in reduced A␤ generation, we transfected N2a cells stably expressing APP695 with
TFEB or vector control, and examined APP processing. TFEBtransfected cells demonstrated increased lysosome abundance, as
indicated by upregulation of lysosomal proteins (Figure 6 A, B)
driven by eightfold overexpression of TFEB, as we observed previously in C17.2 cells (Xiao et al., 2014). TFEB-transfected cells
demonstrated a reduction in APP abundance, as well as reduced
levels of ␣- and ␤-CTFs and sAPP␣ in the medium (Fig. 6C,D).
This was not associated with a change in APP transcript (TFEB/
GAPDH ) mRNA 1.04 ⫾ 0.04-fold in TFEB transfected vs 1.0 ⫾
0.01-fold in control, p ⫽ 0.38, N ⫽ 3 per group), indicating that
TFEB stimulates increased degradation of APP, which is consistent with the observations in TFEB-transduced hippocampi (Fig.
2). Confocal imaging of a dual fluorescent APP construct (Sannerud et al., 2011) also demonstrated a qualitative upregulation
of lysosome abundance with reduction in full-length APP protein
in TFEB-transfected cells, along with increased localization of
APP in lysosomes (Fig. 6E). Colocalization of full-length APP
(bearing both blue and green fluorescent tags) with LysoTracker
Red-labeled lysosomes (see arrows) was qualitatively observed to
be upregulated in TFEB-expressing cells (Fig. 6E, arrows). This
was associated with reduced A␤ abundance, both intracellularly
(Fig. 7A) and in the medium (Fig. 7B). Importantly, TFEBtransfected cells demonstrated a reduction in A␤ appearance in
the medium (Fig. 7C,D), indicating that TFEB primarily attenuates A␤ generation, and reduced intracellular A␤ levels are not a
result of increased A␤ secretion.
Figure 4. Neuronal TFEB transduction reduces amyloid plaque load in APP/PS1 mice. A,
Schematic representation of specific antibodies used in ELISA. B, C, A␤40 and A␤42 levels in
dissected hippocampal tissues from AAV8-CMV-FLAG-TFEB (TFEB) and AAV8-CMV-GFP (GFP)transduced mice (10 months of age). Tissue was homogenized first in PBS (soluble levels, B),
then in 5 mM guanidine (insoluble levels, C) quantified with ELISA assay. HJ2 and HJ7.4 antibodies were used for capture A␤40 and A␤42, respectively, and HJ5.1 antibody was used for
detection. Total A␤ levels were also measured with a combination of HJ5.1 antibody for capture
and HJ3.5 antibody for detection, as indicated in the schematic. N ⫽ 8 mice per group; *p ⬍
0.05, **p ⬍ 0.01. D, Representative X-34-stained images from APP/PS1 mice treated as in A.
The area of the hippocampus is outlined with a dotted line. E, F, Quantification of X-34-stained
plaque burden in the hippocampus (HPC) in mice treated as in A (E) and plaque burden stratified
by sex (F ). N ⫽ 14 (6 male and 8 female) mice per group;*p ⬍ 0.05, **p ⬍ 0.01.

TFEB accelerates APP flux down the endosomelysosome pathway
The intracellular itinerary of APP follows a pathway from the
Golgi (trans-Golgi network), wherein it is post-translationally
4
G, Representative A␤-immunostained images from mice treated as in B. H, I, Quantification of
A␤-stained plaque burden in the hippocampus in mice treated as in A (H) and plaque burden
stratified by sex (I). N ⫽ 14 (6 male and 8 female) mice per group; *p ⬍ 0.05, **p ⬍ 0.01. HPC,
Hippocampus; CTX, cortex.
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Figure 5. Neuronal TFEB transduction reduces levels of APP, its CTFs, and A␤ species in wild-type mice. A, B, Immunoblot (A) with quantitation (B) of APP, and its ␣- and ␤-CTFs in wild-type
mouse hippocampi transduced with AAV8-CMV-FLAG-TFEB (TFEB) or AAV8-CMV-GFP (GFP) at 8 months of age. N ⫽ 3 per group; *p ⬍ 0.05. C, A␤40 and A␤42 levels in dissected hippocampal
tissues homogenized in RIPA buffer, from mice transduced as in A. HJ2 and HJ7.4 antibodies were used for capture A␤40 and A␤42, respectively, and HJ5.1 antibody was used for detection. N ⫽
6 per group; *p ⬍ 0.05.

Figure 6. TFEB expression increases lysosomes and reduces levels of APP and its cleaved CTFs, in vitro. A, B, Immunoblots (A) with quantification (B) of lysosomal proteins in
N2a-APP695 cells transfected with TFEB or vector control (for 48 h). C, D, Immunoblot (C) with quantitation (D) of APP and its ␣- and ␤-CTFs and of sAPP␣ fragment in the overlying
medium, collected over a duration of 6 h in cells treated as in A. N ⫽ 3 per group; *p ⬍ 0.05, **p ⬍ 0.01. E, N2a cells were transfected with a dual fluorescent APP construct (Sannerud
et al., 2011) with or without the TFEB construct and stained with LysoTracker Red. As shown in these confocal images, colocalization of full-length APP (both blue and green tags) with
LysoTracker Red-labeled lysosomes (see arrows) was qualitatively increased in TFEB-expressing cells (see arrows) compared with empty vector-expressing cells.
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al., 2012). At various time points post rewarming, the cells were treated with
2-mercaptoethanesulfonic acid to remove
cell-surface biotinylated APP molecules,
permitting assessment of kinetics of appearance and subsequent degradation of
total internalized biotin-tagged APP via
streptavidin capture and immunoblotting. As shown in Figure 8, A and B, cells
transfected with TFEB demonstrated
reduced levels of both surface and internalized APP, such that the ratio of internalized to surface APP was not altered
compared with control.
To determine whether the reduced
steady-state levels of APP are due to accelerated endocytosis or enhanced flux into
the lysosomes for degradation, we determined the kinetics of intracellular APP
appearance in this assay (Fig. 8C,D). Interestingly, APP was rapidly endocytosed
and the rate of increase of intracellular
APP levels (from T ⫽ 1 to T ⫽ 7.5 min)
was not different between TFEB-expreFigure 7. TFEB expression attenuates A␤ generation, in vitro. A, B, Abundance of A␤40 and A␤42 species in the cell lysates (A) ssing cells and controls (Fig. 8C,D). These
and medium (B) in N2a-APP695 cells transfected with TFEB or vector control. C, D, Accumulation of A␤40 (C) and A␤42 (D) species
data are consistent with a lack of effect of
in the overlying medium of cells treated as in A, over the indicated duration. N ⫽ 5 per group; *p ⬍ 0.05, **p ⬍ 0.01.
TFEB on clathrin-mediated endocytosis,
consistent with our previous observations
modified after synthesis in the ER, to the plasma membrane
(Xiao et al., 2014). To determine whether TFEB expression affects
where it can be cleaved via a nonamyloidogenic ␣-cleavage. Althe kinetics of other transmembrane proteins taken up by
ternatively, APP can be endocytosed, and multiple studies have
clathrin-mediated endocytosis, we examined the uptake of exogdemonstrated that endocytosis of APP is essential for its colocalenously applied biotin-labeled transferrin. Transferrin binds to the
ization with ␤- and ␥-secretases within endosomes and multransferrin receptor and is endocytosed followed by recycling
tivesicular bodies (formed by trafficking of endosomes into
to the cell surface (Ciechanover et al., 1983). The kinetics of
intraluminal vesicles via sequential activity of endosomal-sorting
intracellular appearance of transferrin was not affected by
complexes required for transport, which are the primary sites for
TFEB expression (Fig. 8E), confirming that TFEB does not
accelerate clathrin-mediated endocytosis.
A␤ generation via amyloidogenic cleavage; Rajendran and AnnIn contrast, internalized APP levels at 30 min were 32% lower
aert, 2012). Studies have suggested that impairment in endosomal flux, likely secondary to lysosome dysfunction, results in
in TFEB-transfected cells versus 14% lower in control vectorincreased transit time within this organelle, which increases the
transfected cells from their respective peak levels at 7.5 min ( p ⫽
propensity for ␤- and ␥-cleavage and, hence, A␤ generation
0.017, n ⫽ 3 experimental trails per group), suggesting that TFEB
(Cataldo et al., 2000; Rajendran and Annaert, 2012; Morel et al.,
accelerates degradation of APP, which is targeted for lysosomal
2013; Peric and Annaert, 2015). Indeed, after endocytosis, studies
degradation, in contrast to transferrin that gets recycled to the cell
have demonstrated that a significant proportion of APP is tarsurface (Ciechanover et al., 1983). Together with the observed
geted to the lysosomes (Benowitz et al., 1989; Haass et al., 1992;
reduction in APP and its various cleaved fragments (Fig. 6C,D)
Caporaso et al., 1994) and APP levels rapidly build up in the cells
and attenuated A␤ generation (Fig. 7A–D), these observations
in the presence of lysosomal acidification inhibitors (Golde et al.,
suggest that TFEB expression does not affect APP endocytosis,
but stimulates increased flux of endocytosed APP down the
1992), suggesting that lysosomal degradation drives APP proteolysis to preclude formation of A␤ peptides (Caporaso et al.,
endosome-lysosome pathway without buildup of APP protein in
1992). Given previous reports that TFEB expression can stimuintracellular compartments, resulting in its lysosomal degradalate endocytosis ( Peña-Llopis et al., 2011), a potential adverse
tion and reduced abundance of APP at steady state.
consequence of TFEB activation could be increased APP endocytosis resulting in enhanced ␤- and ␥-cleavage and accelerated A␤
TFEB enhances lysosomal degradation of APP
generation, as observed with other experimental manipulations
To assess the role of lysosomes in APP degradation, we treated
to stimulate endocytosis (Grbovic et al., 2003; Schneider et al.,
TFEB-transfected (and control) cells with bafilomycin A1 to in2008; Xiao et al., 2012). Alternatively, TFEB may stimulate flux
hibit lysosome acidification and evaluated APP abundance. As
through the endosome-lysosome pathway to prevent APP accushown in Figure 9A, bafilomycin treatment resulted in increased
APP levels (by 42% compared with control) and largely premulation in endosomes and stimulate its proteolysis in lysovented the TFEB-induced reduction in APP abundance (Fig.
somes. To evaluate these possibilities, we examined the effect of
9 A, B). This was associated with increase in both ␣- and ␤-CTF
TFEB on APP internalization. N2a-APP95 cells were transfected
levels (Fig. 9 A, C,D) as well as increased generation of A␤40 (Fig.
with TFEB or vector control, and cell-surface APP was labeled by
9E) and A␤42 (Fig. 9F ), as inhibiting lysosomal degradation of
biotinylation at 4°C (to prevent endocytosis), followed by reAPP makes it increasingly available as a substrate for processing
warming to stimulate its internalization by endocytosis (Xiao et
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Figure 8. TFEB expression reduces steady-state cell-surface and intracellular APP levels without altering its endocytosis. A, B, Immunoblot (A) and quantitation (B) of cell-surface and
internalized APP in N2a-APP695 cells transfected with TFEB or vector control, after cell-surface APP was labeled by biotinylation at 4°C (to prevent endocytosis) followed by rewarming (to 37°C) to
stimulate its internalization by endocytosis (for 10 min). Cell-surface APP was assessed in cells maintained at 4°C. To assess internalized APP, cells were treated with 2-mercaptoethanesulfonic acid
to remove cell-surface biotinylated APP molecules, followed by streptavidin capture and immunoblotting (see Materials and Methods). Inset shows ratio of internalized to surface APP; *p ⬍ 0.05.
C–E, Immunoblot (C) and quantitation (D) of intracellular APP as a fraction of cell-surface APP to demonstrate kinetics of intracellular A␤ in cells transfected as in A and kinetics of uptake of
biotinylated transferrin [immunoblot (C) with quantitation (E)] in cells treated as in A. N ⫽ 3 per group. No statistically significant differences were observed by two-way ANOVA.

via the secretases. We next determined APP half-life by treating
cells with cycloheximide to inhibit protein synthesis and follow
APP abundance. As shown in Figure 9, G and H, TFEB transfection reduced APP half-life by 42% compared with control indicating enhanced APP degradation. Intriguingly, the levels of
exogenous TFEB also declined rapidly, consistent with the observations that activated TFEB is degraded rapidly (RoczniakFerguson et al., 2012) possibly via the ubiquitin-proteasome
pathway (Maia et al., 2015). It was also interesting to note that the
abundance of APP in bafilomycin-treated TFEB-expressing cells
was lower than the respective levels in vector controls (Fig. 9B),
again pointing to the reduction in steady-state levels of APP with
TFEB expression, before application of bafilomycin to inhibit
lysosome acidification. Expectedly, this resulted in a relative decline in the CTFs and A␤ peptides in this setting (Fig. 9C–F ).
As described previously (Caporaso et al., 1992), inhibition of
lysosome acidification with bafilomycin A1 prolonged APP halflife, demonstrating that a significant fraction of APP is degraded
via the lysosomes (Fig. 9I–K ). Importantly, APP half-life was also
markedly prolonged by 61% in the presence of bafilomycin A1 in
TFEB-transfected cells (Fig. 9L). In summary, these studies dem-

onstrate that TFEB expression accelerates endogenous pathways
for holo-APP degradation via lysosomes, preventing its amyloidogenic processing into A␤.

Discussion
Contemporary approaches to reducing A␤ generation in neurons
have focused upon shifting APP processing to nonamyloidogenic
pathways or sorting APP away from the endosomes where amyloidogenic cleavage takes place (Haass et al., 2012). Our study
demonstrates the efficacy of accelerating holo-APP degradation
in lysosomes as a strategy to reduce A␤ generation. Indeed, exogenous TFEB expression stimulates lysosome biogenesis in vitro,
reduces full-length APP and its cleaved fragments, attenuates A␤
generation and release in the medium (Figs. 6, 7), and markedly
shortens APP half-life (Fig. 9) in a lysosome-dependent manner.
These effects are likely secondary to acceleration of lysosomal
degradation of endocytosed APP, as suggested by reduction of
steady-state APP at both the surface and within intracellular
compartments (Fig. 8), and reduced APP half-life with TFEB
expression (Fig. 9). Mirroring these in vitro findings, AAVmediated neuronal TFEB transduction in the hippocampus of
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Figure 9. TFEB expression enhances lysosomal degradation of APP. A–F, Immunoblot (A) with quantitation of APP (B), ␣-CTF (C), ␤-CTF (D), A␤40 (E), and A␤42 (F) in N2a-APP695 cells transfected with TFEB or
vectorcontrolandculturedinthepresenceofbafilomycinA1(Baf)ordiluentfor4h.Pvaluesshownarebyposthoctestafterone-wayANOVA.G,N2a-APP695cellsweretransfectedwithTFEBorvectorcontrolandtreatedwith
cycloheximide(CHX;50 g/ml)att⫽0.CellswerecollectedattheindicatedtimestoevaluateAPPabundance.H,APPabundanceexpressedasapercentageofbaseline(t⫽0afteradditionofcycloheximide)incellstreated
asinC.N⫽3pergroup.Insetshowshalf-lifeofAPP;*p⬍0.05.I,N2a-APP695cellsweretransfectedwithTFEBorvectorcontrol,andwerepretreatedwithbafilomycinA1ordiluent(100nM for30min)andtreatedwith
cycloheximide (50 g/ml) at t ⫽ 0. Cells were collected at the indicated times to evaluate APP abundance. J, K, Quantitation of APP abundance at various times in cells treated as in I, in the vector-transfected (J) or
TFEB-transfected(K)groups.N⫽4pergroup.L,Half-lifeofAPPinbafilomycinA1-treatedcellsexpressedasapercentageofdiluent-treatedgroup.N⫽4pergroup;*p⬍0.05.

APP/PS1 mice also drives upregulation of lysosome abundance
with reduction in APP and its cleaved fragments (Figs. 1, 2). This
translates into reduced steady-state ISF A␤ levels (Fig. 3) and
attenuated amyloid deposits specifically in the AAV-targeted hip-

pocampus (Fig. 4). Remarkably, the magnitude of reduction in
ISF A␤ and amyloid plaque load with neuronal TFEB transduction compares favorably with that observed with astrocytic TFEB
transduction to accelerate A␤ degradation (Xiao et al., 2014),
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highlighting the potential for therapeutic synergy with these dual
approaches.
Our data indicate that lysosomal degradation of APP is an
important component of APP metabolism. Indeed, studies with
pulse-chase radioactive labeling of APP revealed that full-length
APP is degraded with a half-life of ⬃90 min (consistent with our
observations in Fig. 9H ), and inhibition of lysosomal acidification with chloroquine prolongs its half-life (Caporaso et al.,
1992) and accumulation within lysosomes (Caporaso et al.,
1994). Remarkably, chloroquine treatment resulted in marked
increase in the appearance of A␤ in the medium, providing the
earliest clue on the essential role of lysosomes in facilitating
breakdown of APP. Also, biotinylated cell-surface APP was recovered within lysosomes, along with its various CTFs, providing
further evidence that APP and its CTFs are targeted to lysosomes
(Haass et al., 1992). Indeed, BACE1, the rate-limiting step for
amyloidogenic cleavage of APP, and its product, ␤CTF, the precursor for A␤, are also degraded within lysosomes (Chen et al.,
2000; Koh et al., 2005), indicating that flux into the lysosomes
may be the critical determinant of whether APP metabolism leads
to A␤ generation or its nonamyloidogenic degradation.
Endocytosis of APP via clathrin-mediated mechanisms is essential for A␤ generation, and endosomes are the primary sites
for its amyloidogenic processing (Koo and Squazzo, 1994; Perez
et al., 1999; Schneider et al., 2008). Given that endosomal cargo is
typically sorted to other vesicles or targeted to lysosomes for degradation ( Théry et al., 2002; Hurley, 2008), the mechanisms
whereby APP is channeled toward A␤ generation rather than
lysosomal degradation bear careful examination. Endocytosis is
accelerated with upregulation of endocytotic GTPase effectors,
rab5 and rab7, in vulnerable regions of the brain from individuals
with mild cognitive impairment and AD (Ginsberg et al., 2010)
and gain-of-function polymorphisms in endocytosis pathway
genes confer increased risk for AD (Harold et al., 2009). Concomitantly, studies also point to impairment in flux through the
endosome-lysosome pathway (for review, see Peric and Annaert,
2015) resulting in accumulation of endosomes (as observed in
neurons in humans before development of AD pathology;
Cataldo et al., 2000) and in transdifferentiated neurons from patients’ skin fibroblasts (Israel et al., 2012). Emerging evidence
indicates that lysosome dysfunction may underlie the observed
impairment in endosomal flux (Funk and Kuret, 2012; Peric and
Annaert, 2015). These events permit prolonged colocalization of
APP with the amyloidogenic ␤- and ␥-secretase machinery to
permit A␤ generation (Rajendran and Annaert, 2012). Our findings indicate that activation of TFEB, a transcriptional activator
of multiple lysosomal and trafficking genes (Palmieri et al., 2011;
Settembre et al., 2013a), corrects the underlying lysosomal impairment to stimulate flux through the endosome-lysosome
pathway to enhance APP degradation and reduce A␤ generation.
Our data do not exclude the possibility that TFEB enhances a
pathway for trafficking of APP directly from Golgi to lysosomes,
while bypassing the plasma membrane and endosomes, where
amyloidogenic cleavage of APP takes place. Consistent with this
hypothesis, APP has been demonstrated to interact with sortilin,
a Vps10p family receptor, in a manner that increases its lysosomal
targeting and reduces its abundance in lipid rafts, the primary
sites for APP endocytosis (Kojro et al., 2001; Yang et al., 2013)
and with a related protein, SORLA, which regulates APP localization in endosomes and A␤ generation in neurons (Burgert et al.,
2013). It is intriguing to speculate that proteins may regulate
physiologic trafficking of APP to the lysosomes in a manner
mimicking their role in targeting of other lysosomal proteins
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(Coutinho et al., 2012; Burgert et al., 2013); further studies will be
required to address this systematically.
TFEB also stimulates autophagy (Settembre et al., 2011), a
lysosomal degradative pathway that is upregulated in advanced
stages of AD pathology (Nixon and Yang, 2011). In neurons, both
endosomes and autophagosomes traffic to the lysosomes (Lee et
al., 2011), and accumulation of autophagosomes due to impaired
fusion with lysosomes may also contribute to enhanced A␤ generation (Yu et al., 2005). A careful examination of neuronal autophagy with modulation of autophagic flux in rat cortical
neurons revealed that while interventions to induce autophagosome formation did not affect APP metabolism, impairment in
lysosome function increased APP-␤CTF accumulation with increased A␤ generation, suggesting that accumulation of autophagosomes rather than upregulation of autophagosome formation
accelerates amyloidogenic APP processing (Boland et al., 2010).
Importantly, TFEB stimulates autophagosome-lysosome fusion
and degradation of autophagosome contents (Settembre et al.,
2011). Therefore, while we did not directly examine the effects of
TFEB activation on neuronal autophagy, our data are also consistent with efficient trafficking of APP into the lysosomes down
this pathway to attenuate A␤ generation.
Recently, AAV-mediated neuronal TFEB activation was not
found to affect amyloid plaque deposition in the 5XFAD mouse
model, whereas TFEB activation was sufficient to drive clearance
of Tau aggregates to attenuate AD pathology (Polito et al., 2014).
Conceivably, the lack of effect of TFEB activation on amyloid
pathology is a function of the rapid development of amyloid
pathology in this model (within a few weeks after birth), compared with the APP/PS1 mice where amyloid plaques first appear
at 6 months of age (Yan et al., 2009) or the differences in the level
of TFEB transduction and activation. Indeed, other studies have
demonstrated that inhibition of GSK3␣ and ␤ isoforms restores
lysosomal acidification with attenuation of A␤ levels and plaque
pathology in the 5XFAD model with increased APP degradation
(Avrahami et al., 2013), likely driven by TFEB activation (Parr et
al., 2012).
It is interesting to note that A␤ half-life was also reduced with
neuronal TFEB expression (Fig. 3 A, B). Indeed, neurons also take
up and degrade A␤, albeit their contribution to A␤ removal from
the ISF is proportionately smaller compared with that of glial cell
types (Kanekiyo and Bu, 2014). TFEB transduction in neurons
may stimulate A␤ uptake by macropinocytosis (Holmes et al.,
2013) as we have previously observed in TFEB-transduced astrocytes (Xiao et al., 2014).
Our study highlights the therapeutic potential of neuronal
TFEB activation to reduce A␤ generation and amyloid plaque
pathology. While evidence for endosome-lysosome pathway dysfunction in human AD is predominantly correlative, recent work
demonstrates that A␤ levels in the CSF increase at the time of
initial plaque deposition in AD animal models (Maia et al., 2015).
This is followed by a subsequent decline in CSF A␤, believed to be
from A␤ sequestration by amyloid plaques. A similar decline in
A␤ is also observed preceding the development of dementia in
patients with dominantly inherited AD (Fagan et al., 2014). These
findings lend further support to increased A␤ generation as an
early driver of pathology and underscore the potential for targeting endosomal-lysosome dysfunction early in AD pathogenesis.
Importantly, we did not observe adverse effects with neuronal
TFEB transduction with the viral gene transfer approach, and no
prior adverse consequences of TFEB expression in CNS cell types
have been described (Tsunemi et al., 2012; Decressac et al., 2013;
Polito et al., 2014; Xiao et al., 2014). Nevertheless, examination of

Xiao et al. • Neuronal TFEB Expression Attenuates A␤ Generation

the effects of global TFEB activation on neuronal pathology and
cognitive parameters over long-term studies is warranted to further assess its therapeutic potential. A strategy of TFEB-mediated
suppression of A␤ generation in neurons is likely to be synergistic
with acceleration of A␤ uptake and degradation by astrocytes
(Xiao et al., 2014) in lowering ISF A␤ levels. In this context,
studies are also needed to determine the effect of exogenous
TFEB on microglial phagocytosis of amyloid material, with its
potential to accelerate removal of amyloid deposits, as a veritable
arm of a multipronged approach to therapeutically target TFEB
activation in multiple CNS cell types in AD.
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